Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Stivarga (regorafenib)
i
Other names:
BAY 73-4506, BAY-734506, BAY 734506, BAY734506
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(65)
News
Trials
Company:
Amgen, Bayer
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
dasatinib (215)
sorafenib (180)
anlotinib (139)
sunitinib (139)
ponatinib (98)
lenvatinib (90)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
pexidartinib (6)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
vorolanib (1)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
SKLB-1028 (0)
dasatinib (215)
sorafenib (180)
anlotinib (139)
sunitinib (139)
ponatinib (98)
lenvatinib (90)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
pexidartinib (6)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
vorolanib (1)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
SKLB-1028 (0)
›
Associations
(65)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
SDHB deletion
Gastrointestinal Stromal Tumor
SDHB deletion
Gastrointestinal Stromal Tumor
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.